1. Home
  2. ARVN vs IGR Comparison

ARVN vs IGR Comparison

Compare ARVN & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.26

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Logo CBRE Global Real Estate Income Fund of Beneficial Interest

IGR

CBRE Global Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$10.77

Market Cap

693.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
IGR
Founded
2015
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
693.0M
IPO Year
2018
2003

Fundamental Metrics

Financial Performance
Metric
ARVN
IGR
Price
$7.26
$10.77
Analyst Decision
Buy
Analyst Count
16
0
Target Price
★ $13.93
N/A
AVG Volume (30 Days)
★ 646.8K
497.7K
Earning Date
11-04-2026
01-01-0001
Dividend Yield
N/A
★ 13.93%
EPS Growth
★ 58.84
N/A
EPS
★ 1.70
N/A
Revenue
★ $262,600,000.00
N/A
Revenue This Year
$12.76
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.54
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.74
$4.15
52 Week High
$14.22
$13.67

Technical Indicators

Market Signals
Indicator
ARVN
IGR
Relative Strength Index (RSI) 43.63 49.43
Support Level $6.74 $4.54
Resistance Level $7.74 $13.67
Average True Range (ATR) 0.36 0.22
MACD 0.08 -0.24
Stochastic Oscillator 51.43 19.44

Price Performance

Historical Comparison
ARVN
IGR

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

Share on Social Networks: